Clinical Trial Update: Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating darbepoetin alfa administered once every four weeks for anemia of cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Cancer

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Anemia | Phase 2 | Status: COMPLETED